Gaining Efficiency in Clinical Trials With Cardiac Biomarkers

被引：8

作者：

Januzzi, James L., Jr. ^{[1
,2
]}

Canty, John M. ^{[3
,4
]}

Das, Saumya ^{[1
]}

DeFilippi, Christopher R. ^{[5
]}

Gintant, Gary A. ^{[6
]}

Gutstein, David E. ^{[7
]}

Jaffe, Allan ^{[8
,9
]}

Kaushik, Emily P. ^{[10
]}

Leptak, Christopher ^{[11
]}

Mehta, Cyrus ^{[12
,13
]}

Pina, Ileana ^{[14
]}

Povsic, Thomas J. ^{[15
,16
]}

Rambaran, Curtis ^{[17
]}

Rhyne, Rhonda F. ^{[18
]}

Salas, Maribel ^{[17
,19
]}

Shi, Victor C. ^{[20
]}

Udell, Jacob A. ^{[21
,22
]}

Unger, Ellis F. ^{[23
]}

Zabka, Tanja S. ^{[24
]}

Seltzer, Jonathan H. ^{[25
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Cardiol Div, Boston, MA 02115 USA

[2] Baim Inst Clin Res, Boston, MA USA

[3] Univ Buffalo, Div Cardiovasc Med, Buffalo, NY USA

[4] Western New York Hlth Care Syst, Dept Vet Affairs, Buffalo, NY USA

[5] Inova Heart & Vasc Inst, Falls Church, VA USA

[6] AbbVie Pharmaceut, Dept Integrat Pharmacol Integrated Sci & Technol, Cambridge, MA USA

[7] Janssen Pharmaceut, Cardiovasc Metab Discovery, Titusville, NJ USA

[8] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA

[9] Mayo Clin, Lab Med & Pathol, Rochester, MN USA

[10] Takeda Pharmaceut, Global Drug Safety Res & Evaluat, Boston, MA USA

[11] US FDA, Biomarker Qualificat Program, Off New Drugs, Ctr Drug Dev & Res, Silver Spring, MD USA

[12] Harvard TH Chan Sch Publ Hlth, Boston, MA USA

[13] Cytel Inc, Boston, MA USA

[14] Wayne State Univ, Detroit, MI USA

[15] Duke Univ, Duke Clin Res Inst, Durham, NC USA

[16] Duke Univ, Dept Med, Durham, NC USA

[17] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[18] Prevencio Inc, Kirkland, WA USA

[19] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[20] Novartis Pharmaceut, Basel, Switzerland

[21] Univ Toronto, Womens Coll Hosp, Cardiovasc Div, Toronto, ON, Canada

[22] Univ Toronto, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Toronto, ON, Canada

[23] US FDA, Off Cardiol Hematol Endocrinol & Nephrol, Off New Drugs, Ctr Drug Dev & Res, Silver Spring, MD USA

[24] Genentech Inc, Dev Sci Safety Assessment, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA

[25] WCG Clin & WCG ACI Clin, Bala Cynwood, PA USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2021年 / 77卷 / 15期

关键词：

biomarker; clinical trials; biobanking; ROSUVASTATIN MULTINATIONAL TRIAL; BRAIN NATRIURETIC PEPTIDE; SAMPLED BLOOD ARCHIVE; HEART-FAILURE; CORONARY; THERAPY; ANGIOGRAPHY; PREDICTION; SURVIVAL; BENEFIT;

D O I：

10.1016/j.jacc.2021.02.040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The momentum of cardiovascular drug development has slowed dramatically. Use of validated cardiac biomarkers in clinical trials could accelerate development of much-needed therapies, but biomarkers have been used less for cardiovascular drug development than in therapeutic areas such as oncology. Moreover, there are inconsistences in biomarker use in clinical trials, such as sample type, collection times, analytical methods, and storage for future research. With these needs in mind, participants in a Cardiac Safety Research Consortium Think Tank proposed the development of international guidance in this area, together with improved quality assurance and analytical methods, to determine what biomarkers can reliably show. Participants recommended the development of systematic methods for sample collection, and the archiving of samples in all cardiovascular clinical trials (including creation of a biobank or repository). The academic and regulatory communities also agreed to work together to ensure that published information is fully and clearly expressed.

引用

页码：1922 / 1933

页数：12

共 50 条

[21] Clinical Use of Biomarkers in Cardiac Amyloidosis
Lalario, Andrea
Saro, Riccardo
Sinagra, Gianfranco
Merlo, Marco
Porcari, Aldostefano
HEART FAILURE CLINICS, 2024, 20 (03) : 283 - 294
[22] Evaluating biomarkers for prognostic enrichment of clinical trials
Kerr, Kathleen F.
Roth, Jeremy
Zhu, Kehao
Thiessen-Philbrook, Heather
Meisner, Allison
Wilson, Francis Perry
Coca, Steven
Parikh, Chirag R.
CLINICAL TRIALS, 2017, 14 (06) : 629 - 638
[23] The role of biomarkers in clinical trials for Alzheimer disease
Thal, LJ
Kantarci, K
Reiman, EM
Klunk, WE
Weiner, MW
Zetterberg, H
Galasko, D
Praticò, D
Griffin, S
Schenk, D
Siemers, E
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2006, 20 (01) : 6 - 15
[24] Design and Execution of Clinical Trials in the Cardiac Intensive Care Unit
Pierce, Jacob B.
Applefeld, Willard N.
Senman, Balimkiz
Loriaux, Daniel B.
Lawler, Patrick R.
Katz, Jason N.
CRITICAL CARE CLINICS, 2024, 40 (01) : 193 - 209
[25] Biomarkers and Risk Models in Cardiac Surgery
Shahian, David M.
Grover, Frederick L.
CIRCULATION, 2014, 130 (12) : 932 - 935
[26] Leveraging machine learning predictive biomarkers to augment the statistical power of clinical trials with baseline magnetic resonance imaging
Lou, Carolyn
Habes, Mohamad
Illenberger, Nicholas A.
Ezzati, Ali
Lipton, Richard B.
Shaw, Pamela A.
Stephens-Shields, Alisa J.
Akbari, Hamed
Doshi, Jimit
Davatzikos, Christos
Shinohara, Russell T.
BRAIN COMMUNICATIONS, 2021, 3 (04)
[27] Cardiac Arrest and the Limitations of Clinical Trials
Sanders, Arthur B.
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (09) : 850 - 851
[28] Biomarkers as Surrogate End Points in Heart Failure Trials
Felker, G. Michael
HEART FAILURE CLINICS, 2011, 7 (04) : 501 - +
[29] Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease
Keating, S. M.
Deng, X.
Fernandes, F.
Cunha-Neto, E.
Ribeiro, A. L.
Adesina, B.
Beyer, A. I.
Contestable, P.
Custer, B.
Busch, M. P.
Sabino, E. C.
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 199 : 451 - 459
[30] The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials
Zhang, Zhi-Jiang
Yuan, Jingping
Bi, Yongyi
Wang, Chunhong
Liu, Yu
PHARMACOLOGICAL RESEARCH, 2019, 141 : 551 - 555

← 1 2 3 4 5 →